Table 1

Pre-Procedural OCT Findings in ISR Lesions

Total
(N = 152)
Presence of Periprocedural MI
(n = 11)
Absence of Periprocedural MI
(n = 141)
p Value
Stent duration, months52.8 (17.5–86.9)87.5 (80.2–142.7)51.9 (16.3–83.8)0.008
MLA, mm21.5 (1.0–2.0)1.2 (1.0–1.8)1.5 (1.0–2.0)0.596
Stent area at the MLA, mm27.1 (5.7–8.5)7.2 (6.7–8.0)7.1 (5.7–8.5)0.586
%Intimal hyperplasia80.1 (69.2–86.5)81.3 (75.0–87.3)80.0 (68.5–86.4)0.355
Lipid neointima139 (91)11 (8)129 (91)0.361
Calcium20 (13)1 (9)19 (14)0.650
Minimal thickness of fibrous cap, μm80.0 (60.0–150.0)60.0 (50.0–60.0)90.0 (60.0–150.0)0.016
Thrombi84 (55)10 (91)74 (52)0.010
Red thrombi10 (7)1 (9)9 (6)0.539
Intimal rupture71 (47)9 (82)62 (44)0.016
In-stent TCFA68 (45)9 (82)59 (42)0.011
Neoatherosclerosis143 (94)11 (100)132 (94)0.499
Neoatherosclerosis without in-stent TCFA or intimal rupture56 (37)0 (0)56 (40)0.005
Malapposition24 (16)1 (9)23 (16)0.342

Values are median (interquartile range) or n (%).

ISR = in-stent restenosis; MI = myocardial infarction; MLA = minimal lumen area; OCT = optical coherence tomography; TCFA = thin-cap fibroatheroma.

  • Neoatherosclerosis is defined as the composite of lipidic neointima, in-stent TCFA, intimal rupture, and in-stent calcification. Continuous variables are compared using the nonparametric, Mann-Whitney test.